Algert Global LLC Acquires New Position in DENTSPLY SIRONA Inc. $XRAY

Key Points

• Algert Global LLC acquired 230,020 shares of DENTSPLY SIRONA during the second quarter, worth approximately $2.44 million; institutional investors collectively own 95.7% of the company.
• Analysts remain cautious, with a consensus “Hold” rating and a $13.54 target price. Recent targets ranged from $14 to $17, while Weiss Ratings maintained a sell rating.
• DENTSPLY SIRONA exceeded quarterly earnings expectations, reporting $0.52 EPS versus the $0.35 consensus and $898 million in revenue, but revenue declined 4.1% year over year and analysts reduced several near-term EPS estimates.

Algert Global LLC acquired a new stake in DENTSPLY SIRONA Inc. (NASDAQ:XRAY - Free Report) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 230,020 shares of the medical instruments supplier's stock, valued at approximately $2,441,000. Algert Global LLC owned about 0.12% of DENTSPLY SIRONA as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently made changes to their positions in XRAY. First Eagle Investment Management LLC increased its holdings in DENTSPLY SIRONA by 3.2% in the fourth quarter. First Eagle Investment Management LLC now owns 14,640,555 shares of the medical instruments supplier's stock valued at $167,342,000 after purchasing an additional 458,744 shares during the last quarter. Edmond DE Rothschild Holding S.A. acquired a new position in shares of DENTSPLY SIRONA during the 2nd quarter worth about $47,780,000. BlackRock Inc. bought a new stake in shares of DENTSPLY SIRONA in the 2nd quarter valued at about $283,405,000. UBS Group AG raised its position in shares of DENTSPLY SIRONA by 63.7% in the 4th quarter. UBS Group AG now owns 1,701,980 shares of the medical instruments supplier's stock valued at $19,454,000 after acquiring an additional 662,000 shares during the period. Finally, Fiduciary Alliance LLC acquired a new stake in shares of DENTSPLY SIRONA in the 1st quarter valued at approximately $4,607,000. Institutional investors own 95.70% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on XRAY. UBS Group decreased their price objective on shares of DENTSPLY SIRONA from $18.00 to $17.00 and set a "buy" rating for the company in a report on Thursday, May 7th. Weiss Ratings reiterated a "sell (e+)" rating on shares of DENTSPLY SIRONA in a report on Monday, August 3rd. Piper Sandler lifted their price target on shares of DENTSPLY SIRONA from $13.00 to $14.00 and gave the stock a "neutral" rating in a research report on Wednesday, July 29th. Mizuho decreased their target price on DENTSPLY SIRONA from $16.00 to $14.00 and set a "neutral" rating for the company in a research note on Wednesday, May 6th. Finally, Barrington Research set a $15.00 price target on DENTSPLY SIRONA in a report on Monday, August 10th. Three analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $13.54.

Insider Activity at DENTSPLY SIRONA

In other DENTSPLY SIRONA news, Director Brian T. Gladden purchased 9,985 shares of the firm's stock in a transaction dated Monday, June 15th. The stock was bought at an average cost of $10.02 per share, with a total value of $100,049.70. Following the purchase, the director directly owned 61,849 shares of the company's stock, valued at $619,726.98. The trade was a 19.25% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Michael J. Barber acquired 15,175 shares of the stock in a transaction dated Thursday, June 11th. The stock was acquired at an average price of $9.88 per share, for a total transaction of $149,929.00. Following the completion of the acquisition, the director directly owned 55,943 shares of the company's stock, valued at $552,716.84. The trade was a 37.22% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last quarter, insiders have bought 35,160 shares of company stock valued at $351,179. 0.46% of the stock is owned by insiders.

DENTSPLY SIRONA News Summary

Here are the key news stories impacting DENTSPLY SIRONA this week:

• Positive Sentiment: Zacks Research increased its FY2026 EPS estimate to $1.50 from $1.41, above the current consensus estimate of $1.41. This is the clearest supportive factor for DENTSPLY SIRONA (XRAY) today.
• Neutral Sentiment: Zacks maintained estimates of $1.50 EPS for FY2027 and $1.64 EPS for FY2028 in its updated forecast set, providing some stability despite reductions to individual periods.
• Negative Sentiment: The firm lowered its Q3 2026 EPS estimate to $0.31 from $0.37 and cut Q4 2026 EPS to $0.40 from $0.41. The Q3 revision is particularly notable because it represents a larger reduction in expected near-term profitability.
• Negative Sentiment: Additional cuts included Q2 2027 EPS to $0.38 from $0.39, Q3 2027 EPS to $0.41 from $0.42, Q4 2027 EPS to $0.39 from $0.40, Q1 2028 EPS to $0.35 from $0.37, Q2 2028 EPS to $0.41 from $0.42, and FY2028 EPS to $1.64 from $1.65.

DENTSPLY SIRONA Price Performance

XRAY stock opened at $11.12 on Friday. The stock has a 50-day moving average price of $12.10 and a two-hundred day moving average price of $11.75. The stock has a market cap of $2.22 billion, a PE ratio of -4.04, a price-to-earnings-growth ratio of 1.39 and a beta of 0.85. The company has a current ratio of 1.63, a quick ratio of 1.07 and a debt-to-equity ratio of 1.48. DENTSPLY SIRONA Inc. has a 1 year low of $9.40 and a 1 year high of $14.86.

DENTSPLY SIRONA (NASDAQ:XRAY - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $0.52 EPS for the quarter, beating analysts' consensus estimates of $0.35 by $0.17. The company had revenue of $898.00 million for the quarter, compared to analyst estimates of $889.93 million. DENTSPLY SIRONA had a positive return on equity of 20.84% and a negative net margin of 14.99%.The company's quarterly revenue was down 4.1% compared to the same quarter last year. During the same period in the previous year, the company posted $0.52 earnings per share. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. Equities analysts forecast that DENTSPLY SIRONA Inc. will post 1.4 EPS for the current fiscal year.

DENTSPLY SIRONA Company Profile

Dentsply Sirona Inc NASDAQ: XRAY is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company's product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.

Want to see what other hedge funds are holding XRAY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DENTSPLY SIRONA Inc. (NASDAQ:XRAY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source